Label updates have been approved by the FDA for the CAR T-cell therapies Breyanzi and Abecma in large B cell lymphoma and ...

Viatris’ presbyopia drug MR-141 (phentolamine ophthalmic solution 0.75%) has met the primary endpoint and all secondary ...

The agency removed some onerous requirements for the complex cancer drugs and reduced restrictions on patients’ ...

The U.S. Food and Drug Administration said on Tuesday that it is investigating reports of two deaths due to acute liver ...

The Polish government’s new draft law on drug reimbursement aims to streamline procedures, empower patients, and ensure ...

Researchers reviewed cancer pain management strategies, including traditional Chinese medicine-based strategies such as acupoint therapies. Chinese researchers explored the role of traditional Chinese ...

Researchers have analyzed clinical trial data and ranked 12 different non-drug physical therapy treatments for knee ...

Investing.com -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) stock gained 2.2% premarket after the company announced that its experimental treatment for Angelman syndrome received Breakthrough ...

Ultragenyx Pharmaceutical received breakthrough therapy designation from the U.S. Food and Drug Administration for its drug GTX-102, which is designed to treat people with Angelman syndrome. Angelman ...

Simon Fraser University researchers are using a new approach to brain imaging that could improve how drugs are prescribed to ...

Only five days after FDA approval of Yutrepia, Liquidia announced its first commercial shipment of the therapy, making prescriptions available to patients at specialty pharmacies. “We have moved with ...

For $45 million upfront, Vor Bio is gaining ex-China rights to RemeGen’s telitacicept, a first-in-class recombinant ...